Ventria Bioscience

Ventria Bioscience is a biotechnology company that specializes in the development and commercialization of plant-made pharmaceuticals. The company was founded in 1993 and is headquartered in Sacramento, California, United States.

History

Ventria Bioscience was established in 1993 with the aim of developing and commercializing plant-made pharmaceuticals. The company's initial focus was on the production of recombinant proteins in plants, a process known as molecular farming or pharming.

Technology

Ventria Bioscience utilizes a proprietary technology platform known as ExpressTec. This technology enables the production of recombinant proteins in the seeds of rice plants. The proteins can then be extracted and purified for use in pharmaceutical applications. ExpressTec has been used to produce a variety of proteins, including lactoferrin, lysozyme, and human serum albumin.

Products

Ventria Bioscience has developed several products using its ExpressTec technology. These include a rehydration solution called InVitria, which contains recombinant human lactoferrin and lysozyme. The company has also developed a line of skincare products under the brand name Vantria, which contain recombinant human lactoferrin.

Controversies

Ventria Bioscience has faced controversy over its use of genetically modified rice plants to produce pharmaceuticals. Critics argue that this could lead to the contamination of the food supply, while the company maintains that it has implemented strict controls to prevent such contamination.

See also

• Biopharming
• Genetically modified crops
• Recombinant DNA

References

<references />

   This article is a biotechnology stub. You can help WikiMD by expanding it!